CSL 1H2022 Earnings Preview: Where next for CSL stock?

CSL Limited (CSL) is Australia's largest drugmaker, one of the world's largest biotech companies, a leader in flu treatments and plasma protein therapies, and a leading provider of in-licensed vaccines. It reports its half-year numbers on Wednesday the 16th of February at 11 am.


COVID-19 has been a headwind for CSL's supply chains and the collection of plasma, an essential raw material used to produce many of CSL's therapies, which account for almost half of CSL's sales. Based on Q3 reports from Japanese competitor Takeda last week, which showed a sizeable reduction in plasma collections, the Covid-19 headwinds are yet to ease.

As part of its plan to diversify earnings and promote long-term growth, CSL is buying Swiss Bio-Tech giant Vifor Pharma for $11.7 billion. Vifor Pharma specialises in iron deficiency and kidney disease. Once the buyout is complete, Vifor's research and development team and pipeline will complement CSL's own.

To help fund the deal, a $6.3bn capital raise was launched in December at $273. As CSL shares are currently trading below the price, a calculation is applied based on a 2% discount to the stock's average price for the five days leading up to the close of the offer. At this point, the price of the raise will be around $255.00 when it closes next week.

Also weighing on the share price a global selloff in growth stocks that commenced in late November. This has resulted in the price/earnings ratio of CSL falling from 44X FY 22s earnings to 37X, offering a more attractive valuation.

At its Annual General Meeting in October, CSL said at a group level they expect revenue growth to be in the range of 2 to 5% over FY21 at constant currency (USD), and net profit after tax (NPAT) was expected to be approximately US$2.15 to $2.25 billion at constant currency.

The market consensus is for CSL to report earnings (NPAT) of A$1.46 billion for 1H2022, with an interim dividend payout of US$1.13 per share.

CSL Daily Chart

Technically, the decline from the $342.75 high of February 2020 appears to be a countertrend after a stunning multi-year rally. Once the correction is complete, the uptrend is expected to resume. 

As such, consider buying CSL shares on a dip into support near $240/230, coming from trend channel support, looking for a retest of resistance at $320.00


CSL Daily Chart 4th of Feb


Source Tradingview. The figures stated areas of the 4th of February 2022. Past performance is not a reliable indicator of future performance. This report does not contain and is not to be taken as containing any financial product advice or financial product recommendation

  1. Open a Forex.com account, or log in if you’re already a customer.
  2. Search for the pair you want to trade in our award-winning platform.
  3. Choose your position and size, and your stop and limit levels.
  4. Place the trade.


Disclaimer: The information on this web site is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement. The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Any references to historical price movements or levels is informational based on our analysis and we do not represent or warranty that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, author does not guarantee its accuracy or completeness, nor does author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions.

Futures, Options on Futures, Foreign Exchange and other leveraged products involves significant risk of loss and is not suitable for all investors. Losses can exceed your deposits. Increasing leverage increases risk. Spot Gold and Silver contracts are not subject to regulation under the U.S. Commodity Exchange Act. Contracts for Difference (CFDs) are not available for US residents. Before deciding to trade forex and commodity futures, you should carefully consider your financial objectives, level of experience and risk appetite. Any opinions, news, research, analyses, prices or other information contained herein is intended as general information about the subject matter covered and is provided with the understanding that we do not provide any investment, legal, or tax advice. You should consult with appropriate counsel or other advisors on all investment, legal, or tax matters. References to Forex.com or GAIN Capital refer to GAIN Capital Holdings Inc. and its subsidiaries. Please read Characteristics and Risks of Standardized Options.

Open an Account